Journal of Osteopathic Medicine January 2025: Comprehensive review of the heart failure management guidelines presented by the American College of Cardiology and the current supporting evidence

Create Account

Availability

On-Demand

Access expires on Dec 31, 2027

Cost

Resident/Student: $0.00

AOA Member: $0.00

Non-Member: $22.00

Military: $17.50

Retired: $17.50

Affiliate/Allied Health Professional: $0.00

Staff: $0.00

Credit Offered

1 AOA Category 1-B Credit

OVERVIEW
Heart failure (HF) is a chronic condition that affects the heart's functional capacity, resulting in symptoms such as fatigue, edema, and dyspnea. It affects millions of adults in the United States and presents challenges in optimizing treatment and coordinating care among clinicians. Additionally, the various classifications for HF and limited research on treatment outcomes in heart failure with midrange ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) further complicate the pharmacological management of patients with this disease. The objectives of this article are to review the pharmacotherapy guidelines for HF provided by the American College of Cardiology (ACC) and offer an update on the current trials conducted on these agents.

Authors: Lia Lazareva; Jay H. Shubrook, DO; Milind Dhond, MD, FACC

OBJECTIVES

Review the pharmacotherapy guidelines for HF provided by the American College of Cardiology (ACC)
Outline the classifications of heart failure
Discuss the likelihood of whether physicians and patients will adhere to the guidelines for the management of heart failure

Expiration Date: December 31, 2027

The AOA designates this activity for a maximum of 1.0 AOA Category 1-B Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.